Intravenous immunoglobulin (IVIg), is an effective anti-inflammatory and immunomodulatory treatment for many autoimmune diseases. In this Review, Lünemann and colleagues catalogue the evidence to support the use of IVIg in several neurological disorders, including Guillain–Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. The authors also address diseases in which IVIg has not proven to be effective, and highlight avenues for future research, including drug development studies and clinical trials.
- Jan D. Lünemann
- Falk Nimmerjahn
- Marinos C. Dalakas